Pharmalittle: Novo bid to block Lilly ad rejected, big PBMs probed

Rise and shine, everybody, one other busy day is on the best way. And it’s getting off to a nice begin right here on the Pharmalot campus, the place clear blue skies and cozy breezes are greeting us. As for the official mascots, they’ve completed retaining passersby at bay and at the moment are fortunately snoozing of their respective corners. As for us, we’re firing up the trusty kettle for one more cuppa stimulation. Our selection right now is Earl Gray, a favourite from our pantry. After all, you’re invited to affix us. For the complete expertise, we at the moment are hawking replicas — have a look. In the meantime, listed below are a couple of gadgets of curiosity. As all the time, do communicate. We admire suggestions, criticism, and suggestions. …

GSK is seeing its return to oncology begin to repay, STAT says. Previously week, a most cancers drug picked up an approval for one more tumor sort, the corporate unveiled the primary information from a world examine of a promising next-generation chemotherapy, and a medication the agency licensed received the limelight in a presidential session at a serious oncology convention. GSK can be awaiting one other anticipated approval within the coming weeks for a brand new lung most cancers drug. That mentioned, GSK continues to be a small participant amongst large drugmakers. Its oncology gross sales final 12 months have been about $2.67 billion, a 43% bounce from the 12 months prior, however lower than one-tenth of the gross sales of Merck’s Keytruda alone.

A Home lawmaker is investigating whether or not the three largest pharmacy profit managers focused unbiased pharmacies with audits in retaliation for supporting a invoice that might require the businesses to regulate funds to the retailers, STAT tells us. James Comer (R-Ky.), who heads the Home Committee on Oversight and Authorities Reform, late final week despatched letters to CVS Caremark, OptumRx, and Categorical Scripts, claiming that unbiased pharmacies “skilled an uncommon surge in burdensome audits” after many overtly backed the laws he launched final 12 months.